financetom
Business
financetom
/
Business
/
Deutsche Bank Gives Its Outlook of Bank of England Policy Action
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Deutsche Bank Gives Its Outlook of Bank of England Policy Action
Oct 22, 2024 12:10 PM

07:38 AM EDT, 10/22/2024 (MT Newswires) -- Deutsche Bank said it now shifted its call to a two-stage rate-cutting cycle at the Bank of England.

In Stage 1, the bank expects the BoE's Monetary Policy Committee to move the Bank Rate sequentially over the next few months, taking the Bank Rate down to 3.75% by May 2025.

Following that, in Stage 2, Deutsche Bank estimates the MPC to move to a quarterly pace of rate cuts all the way down to 3% -- the mid-point of the bank's medium-term neutral rate estimates.

The risk of 50bps rate cuts has risen in recent weeks, but the conditions for 'forceful' rate cuts have yet to be met, and the window for any outsized rate cuts is likely to be small, stated Deutsche Bank.

Importantly, the bank still sees risks skewed to a higher terminal rate -- especially in light of growing expectations of looser fiscal policy in the British Fall Budget -- with the MPC potentially pausing following Stage 1 of the easing cycle, or at 3.75%.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Kazia Therapeutics to Expand Ongoing Phase 1b Breast Cancer Trial
Kazia Therapeutics to Expand Ongoing Phase 1b Breast Cancer Trial
May 26, 2026
09:12 AM EDT, 05/26/2026 (MT Newswires) -- Kazia Therapeutics ( KZIA ) said Tuesday that it plans to expand its ongoing phase 1b clinical trial evaluating paxalisib in combination with standard-of-care therapies in patients with advanced triple-negative breast cancer. The company said that it plans to increase enrolment to 36 patients from 12 patients as it has received encouraging safety,...
Intercontinental Exchange's ICE ETF Hub Receives Regulatory Approval to Operate in Europe, Australia
Intercontinental Exchange's ICE ETF Hub Receives Regulatory Approval to Operate in Europe, Australia
May 26, 2026
09:11 AM EDT, 05/26/2026 (MT Newswires) -- Intercontinental Exchange ( ICE ) said Tuesday that its ICE ETF Hub has obtained regulatory approval to expand operations in Europe and Australia for the receipt and transmission of orders in exchange traded products. The expansion brings the platform to 33 countries and jurisdictions globally, adding coverage across European markets, including Germany, France...
Sector Update: Consumer Stocks Edge Higher Premarket Tuesday
Sector Update: Consumer Stocks Edge Higher Premarket Tuesday
May 26, 2026
09:11 AM EDT, 05/26/2026 (MT Newswires) -- Consumer stocks were edging higher premarket Tuesday, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) inactive and the State Street Consumer Discretionary Select Sector SPDR ETF (XLY) up 0.5%. AutoZone ( AZO ) shares were down more than 5% even after the company posted higher fiscal Q3 net income and...
Dyne Therapeutics Submits FDA Approval Application for Duchenne Drug DYNE-251
Dyne Therapeutics Submits FDA Approval Application for Duchenne Drug DYNE-251
May 26, 2026
09:11 AM EDT, 05/26/2026 (MT Newswires) -- Dyne Therapeutics Inc. ( DYN ) said Tuesday it submitted a Biologics License Application to the US Food and Drug Administration for its experimental Duchenne muscular dystrophy treatment zeleciment rostudirsen, also known as DYNE-251, seeking accelerated approval for patients amenable to exon 51 skipping. The company said it has requested Priority Review from...
Copyright 2023-2026 - www.financetom.com All Rights Reserved